Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis-Reference-Cited by-同舟云学术

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis

Published:2019-05 Issue:5 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Xu Jian¹²,Li Si-Yang¹,Almeida Deepak V.¹,Tasneen Rokeya¹,Barnes-Boyle Kala¹,Converse Paul J.¹,Upton Anna M.³,Mdluli Khisimuzi³,Fotouhi Nader³,Nuermberger Eric L.¹⁴

Affiliation:

1. Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

2. Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, and Beijing Chest Hospital, Capital Medical University, Beijing, China

3. Global Alliance for Tuberculosis Drug Development, New York, New York, USA

4. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

Abstract

Novel regimens combining bedaquiline and pretomanid with either linezolid (BPaL regimen) or moxifloxacin and pyrazinamide (BPaMZ regimen) shorten the treatment duration needed to cure tuberculosis (TB) in BALB/c mice compared to that of the first-line regimen and have yielded promising results in initial clinical trials. However, the independent contribution of the investigational new drug pretomanid to the efficacy of BPaMZ has not been examined, and its contribution to BPaL has been examined only over the first 2 months of treatment.

Funder

Global Alliance for Tuberculosis Drug Development

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00021-19

Reference36 articles.

1. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies

2. Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis

3. Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis

4. Dawson R Harris K Conradie A Burger D Murray S Mendel C Spigelman M. 2017. Efficacy of bedaquiline pretomanid moxifloxacin and PZA (BPAMZ) against DS- and MDR-TB. Abstr Conf Retrovir Opportun Infect 2017 abstr 724LB.

5. Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial;The Lancet Infectious Diseases;2024-09

2. Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs;Nature Communications;2024-08-14

3. A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug‐Resistant and Extensively Drug‐Resistant Mycobacterium tuberculosis;Journal of Clinical Laboratory Analysis;2024-08

4. Contribution of telacebec to novel drug regimens in a murine tuberculosis model;2024-06-27

5. Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis;2024-05-13